Kyverna Therapeutics, a cell therapy company engineering a new class of therapies for serious autoimmune diseases, has appointed Tom Van Blarcom, Ph.D., as senior vice president and head of Research.   Van Blarcom has 15 years of biopharmaceutical industry experience leading research teams which have contributed to multiple chimeric antigen receptor (CAR) T cells and bispecific antibodies currently under clinical evaluation. He replaces Kyverna’s scientific co-founder Jeffrey Greve, Ph.D...